# Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008

> **NCT01333462** · PHASE1 · COMPLETED · sponsor: **NanoBio Corporation** · enrollment: 199 (actual)

## Conditions studied

- Healthy Adult Volunteers

## Interventions

- **BIOLOGICAL:** NB-1008
- **OTHER:** Control

## Key facts

- **NCT ID:** NCT01333462
- **Lead sponsor:** NanoBio Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2009-08
- **Final completion:** 2010-09
- **Target enrollment:** 199 (ACTUAL)
- **Last updated:** 2011-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01333462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01333462, "Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01333462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*